Analyst Ratings For Revance Therapeutics (NASDAQ:RVNC)
Today, William Blair reiterated its Outperform rating on Revance Therapeutics (NASDAQ:RVNC).
Some recent analyst ratings include
- 3/1/2018-William Blair Reiterated Rating of Outperform.
- 1/9/2018-Guggenheim was Downgraded by analysts at Guggenheim from a “Buy ” rating to a ” Hold” rating.
- 1/5/2018-Mizuho Reiterated Rating of Buy.
Recent Insider Trading Activity For Revance Therapeutics (NASDAQ:RVNC)
Revance Therapeutics (NASDAQ:RVNC) has insider ownership of 18.86% and institutional ownership of 91.84%.
- On 11/22/2017 L Daniel Browne, CEO, sold 7,600 with an average share price of $24.94 per share and the total transaction amounting to $189,544.00.
- On 11/7/2017 Lauren P Silvernail, CFO, sold 10,000 with an average share price of $26.83 per share and the total transaction amounting to $268,300.00.
- On 11/7/2017 Mark J Foley, Director, bought 20,000 with an average share price of $26.96 per share and the total transaction amounting to $539,200.00.
- On 10/18/2017 L Daniel Browne, CEO, sold 7,662 with an average share price of $26.16 per share and the total transaction amounting to $200,437.92.
- On 10/12/2017 Lauren P Silvernail, CFO, sold 11,164 with an average share price of $26.67 per share and the total transaction amounting to $297,743.88.
- On 9/20/2017 L Daniel Browne, CEO, sold 7,600 with an average share price of $23.58 per share and the total transaction amounting to $179,208.00.
- On 8/23/2017 L Daniel Browne, CEO, sold 22,800 with an average share price of $22.76 per share and the total transaction amounting to $518,928.00.
Recent Trading Activity for Revance Therapeutics (NASDAQ:RVNC)
Shares of Revance Therapeutics closed the previous trading session at 29.80 down -1.15 3.72% with shares trading hands.
